Cytek Biosciences (CTKB)
(Delayed Data from NSDQ)
$6.20 USD
-0.07 (-1.12%)
Updated May 9, 2024 04:00 PM ET
After-Market: $6.21 +0.01 (0.16%) 6:12 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for Cytek Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 193 | 164 | 128 | 93 | NA |
Cost Of Goods | 84 | 63 | 49 | 41 | NA |
Gross Profit | 109 | 101 | 79 | 52 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 137 | 103 | 70 | 38 | 0 |
Income After Depreciation & Amortization | -28 | -2 | 9 | 14 | 0 |
Non-Operating Income | 14 | 6 | -1 | 1 | NA |
Interest Expense | 2 | 3 | 2 | 0 | NA |
Pretax Income | -16 | 1 | 6 | 14 | NA |
Income Taxes | -4 | -1 | 3 | -5 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -12 | 2 | 3 | 19 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -12 | 3 | 3 | 19 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | 4 | 10 | 14 | 0 |
Depreciation & Amortization (Cash Flow) | 9 | 6 | 1 | 1 | NA |
Income After Depreciation & Amortization | -28 | -2 | 9 | 14 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 135.28 | 138.56 | 81.55 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.04 | 0.03 | 0.09 | NA | NA |
Diluted Net EPS (GAAP) | -0.09 | 0.02 | 0.00 | NA | NA |
Fiscal Year end for Cytek Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 58.23 | 48.00 | 49.69 | 37.09 |
Cost Of Goods | NA | 25.19 | 20.82 | 21.53 | 16.05 |
Gross Profit | NA | 33.05 | 27.18 | 28.16 | 21.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 33.18 | 33.60 | 37.29 | 33.20 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.13 | -6.42 | -9.13 | -12.16 |
Non-Operating Income | NA | 4.64 | 2.83 | 2.94 | 3.80 |
Interest Expense | NA | 0.39 | 0.60 | 0.41 | 0.67 |
Pretax Income | NA | 4.11 | -4.19 | -6.60 | -9.04 |
Income Taxes | NA | -1.39 | 2.27 | -2.21 | -2.23 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 5.50 | -6.46 | -4.39 | -6.81 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 5.50 | -6.46 | -4.39 | -6.81 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 137.58 | 136.17 | 135.92 | 135.49 |
Diluted EPS Before Non-Recurring Items | NA | 0.04 | -0.03 | -0.02 | -0.03 |
Diluted Net EPS (GAAP) | NA | 0.04 | -0.05 | -0.03 | -0.05 |